




Section: 25. Medicines acting on the respiratory tract > 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease

		EMLc	Codes ATC: R03BA02
Indication	Asthma	Code ICD11: CA23	
INN	Budesonide		
Type de médicament	Chemical agent		
Type de liste	Liste de base (EML) (EMLc)		
Formulations	Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler ; 200 µg per actuation in dry powder inhaler Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler ; 200 µg per actuation in pressurized metered dose inhaler		
Historique des statuts LME	Ajouté pour la première fois en 2007 (TRS 950) Modifié en 2009 (TRS 958) Modifié en 2021 (TRS 1035) Modifié en 2025 (TRS 1064)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	beclométasone (Codes ATC: R03BA01) ciclesonide (Codes ATC: R03BA08) fluticasone (Codes ATC: R03BA05) mometasone (Codes ATC: R03BA07)		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets.</a> 		
Wikipédia	<a href="#">Budesonide</a> 		
DrugBank	<a href="#">Budesonide</a> 		

## Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of budesonide on the EML and EMLc: - update the listing description of inhalation delivery systems for consistency across the Model Lists and to better reflect product characteristics; - to remove flunisolide as a therapeutic alternative to budesonide from the EML and EMLc due to low market availability.

